Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Carmen Calfa"'
Autor:
Charles L. Wiseman, Jarrod P. Holmes, Carmen Calfa, Shaker R. Dakhil, Saveri Bhattacharya, George E. Peoples, Markus D. Lacher, Miguel Lopez-Lago, Alex Kharazi, Giuseppe Del Priore, Mingjin Chang, Daniel L. Adams, William V. Williams
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
This Phase I/IIa open-label, single-arm clinical trial addressing advanced, refractory, metastatic breast cancer was conducted at six medical centers in the United States. We repeated inoculations with irradiated SV-BR-1-GM, a breast cancer cell line
Externí odkaz:
https://doaj.org/article/67922cae6ff54870900ebf2a5b42091c
Autor:
Sara A. Hurvitz, Jennifer L. Caswell-Jin, Katherine L. McNamara, Jason J. Zoeller, Gregory R. Bean, Robert Dichmann, Alejandra Perez, Ravindranath Patel, Lee Zehngebot, Heather Allen, Linda Bosserman, Brian DiCarlo, April Kennedy, Armando Giuliano, Carmen Calfa, David Molthrop, Aruna Mani, Hsiao-Wang Chen, Judy Dering, Brad Adams, Eran Kotler, Michael F. Press, Joan S. Brugge, Christina Curtis, Dennis J. Slamon
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
HER2+ breast cancer patients can often develop resistance to trastuzumab and therefore potential combination therapies need to be explored. Here, the authors report the results of a multi-center randomized phase II clinical trial evaluating the patho
Externí odkaz:
https://doaj.org/article/3ed71c9a08f44623be4704bf23a0df55
Autor:
Nadine Norton, Nicholas Fox, Christie-Ann McCarl, Kathleen S. Tenner, Karla Ballman, Courtney L. Erskine, Brian M. Necela, Donald Northfelt, Winston W. Tan, Carmen Calfa, Mark Pegram, Gerardo Colon-Otero, Edith A. Perez, Raphael Clynes, Keith L. Knutson
Publikováno v:
Breast Cancer Research, Vol 20, Iss 1, Pp 1-9 (2018)
Abstract Background Resected HER2 breast cancer patients treated with adjuvant trastuzumab and chemotherapy have superior survival compared to patients treated with chemotherapy alone. We previously showed that trastuzumab and chemotherapy induce HER
Externí odkaz:
https://doaj.org/article/1c1febf941ce45ac8dcb2e8d12e66fb8
Autor:
Ankur Tiwari, Guy Clifton, Carmen Calfa, Gheath Alatrash, Jarrod Holmes, Isabelle Bedrosian, George Peoples, Elizabeth A. Mittendorf
Publikováno v:
Cancer Research. 83:P4-07
INTRODUCTION: The HER2-targeted peptide vaccine nelipepimut-S + GM-CSF (NeuVax) has been shown to be safe, immunogenic, and potentially synergistic with trastuzumab. Here we present the results of a randomized phase 2 trial assessing the ability of n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50fe85efd53cd2603c138e58f94aacef
https://doi.org/10.1158/1538-7445.sabcs22-p4-07-23
https://doi.org/10.1158/1538-7445.sabcs22-p4-07-23
Autor:
Saranya Chumsri, William Williams, Mingjin Chang, Miguel Lopez-Lago, Charles Wiseman, Jarrod Holmes, Chaitali Nangia, Karim Mohammed, Minal Barve, Shaker Dakhil, Bonnie Guerin, Giuseppe Del Priore, Carmen Calfa
Publikováno v:
Cancer Research. 83:P3-07
Background: SV-BR-1-GM is an irradiated allogeneic cell line derived from a hormone receptor-negative (HR-) HER2-positive (HER2+) breast cancer (BC), now engineered to express HLA class I and II antigens, secrete GM-CSF and function as an antigen-pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e65886eb04313f8786de4066bfe8aba1
https://doi.org/10.1158/1538-7445.sabcs22-p3-07-12
https://doi.org/10.1158/1538-7445.sabcs22-p3-07-12
Autor:
Frank J. Penedo, Heidy N. Medina, Patricia I. Moreno, Vandana Sookdeo, Akina Natori, Cody Boland, Matthew P. Schlumbrecht, Carmen Calfa, Jessica MacIntyre, Tracy E. Crane, Sofia F. Garcia
Publikováno v:
JCO Oncology Practice. 18:e1100-e1113
PURPOSE: Describe the feasibility and implementation of an electronic health record (EHR)–integrated symptom and needs screening and referral system in a diverse racial/ethnic patient population in ambulatory oncology. METHODS: Data were collected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e27dc988adaeea72be785b50d39348d1
https://doi.org/10.1200/op.21.00706
https://doi.org/10.1200/op.21.00706
Autor:
Edith A. Perez, Elizabeth A. Mittendorf, Mark Pegram, Carmen Calfa, Winston Tan, Donald Northfelt, Nadine Norton, Courtney L. Erskine, Kathleen S. Tenner, Karla Ballman, Kathleen P. Kemp, Patrick Yeramian, Barath Shreeder, Raphael Clynes, Keith L. Knutson
Supplementary Figure S1 describes the pre-existing antibody responses to tumor antigens in patients with surgically resected HER2+ breast cancer. Supplementary Figure S2 compares the proportion of either the metastatic or adjuvant patients that respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7171c1fe5ead828e1ba4f2f22094ed61
https://doi.org/10.1158/0008-5472.22412151.v1
https://doi.org/10.1158/0008-5472.22412151.v1
Autor:
Edith A. Perez, Elizabeth A. Mittendorf, Mark Pegram, Carmen Calfa, Winston Tan, Donald Northfelt, Nadine Norton, Courtney L. Erskine, Kathleen S. Tenner, Karla Ballman, Kathleen P. Kemp, Patrick Yeramian, Barath Shreeder, Raphael Clynes, Keith L. Knutson
The addition of trastuzumab to chemotherapy extends survival among patients with HER2+ breast cancer. Prior work showed that trastuzumab and chemotherapy augments HER2 extracellular domain (ECD)-specific antibodies. The current study investigated whe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2142aacfa9480e56b1afecd61b3fae47
https://doi.org/10.1158/0008-5472.c.6508374.v1
https://doi.org/10.1158/0008-5472.c.6508374.v1
Autor:
William Williams, Shaker R Dakhil, Carmen Calfa, Jarrod P Holmes, Saveri Bhattacharya, Jason Lukas, Elizabeth Tan-Chui, George E Peoples, Vivek G Sunkari, Markus D Lacher, Charles L Wiseman
Publikováno v:
Cancer Research. 82:P2-14
Background: SV-BR-1-GM is a GM-CSF secreting breast cancer cell line derived from a Grade II (moderately differentiated) breast tumor that also expresses HLA class I & II antigens and is able to function as an antigen-presenting cell. Irradiated SV-B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e12ce2e62b800836e58dc9ed1f114c4
https://doi.org/10.1158/1538-7445.sabcs21-p2-14-02
https://doi.org/10.1158/1538-7445.sabcs21-p2-14-02
Autor:
Saranya Chumsri, Minal Barve, Chaitali Nangia, Bonnie L. Guerin, Jarrod Holmes, Karim Mohammed, John Knecht, Shaker Dakhil, William V. Williams, Charles Wiseman, Mingjin Chang, Miguel Lopez-Lago, John G. Knecht, Kendrith Rowland, Ralph V. Boccia, Giuseppe Del Priore, Carmen Calfa
Publikováno v:
Cancer Research. 83:CT143-CT143
Background: Bria-IMT (SV-BR-1-GM) is an off-the-shelf whole tumor cell therapeutic vaccine engineered to express class I & class II HLAs, secrete GM-CSF, and function as antigen-presenting cells; with subsequent enhancements improving in-vitro charac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::daa3e1f041ddd4123a31bb317c2d118c
https://doi.org/10.1158/1538-7445.am2023-ct143
https://doi.org/10.1158/1538-7445.am2023-ct143